Efficacy of the combination of ipilimumab and nivolumab following progression on pembrolizumab in advanced melanoma with poor risk features

Eur J Cancer. 2017 Apr:75:243-244. doi: 10.1016/j.ejca.2016.12.040. Epub 2017 Feb 24.

Authors

Lavinia Spain¹, Thomas Schmid¹, Martin Gore¹, James Larkin²

Affiliations

¹ Royal Marsden NHS Foundation Trust, United Kingdom.
² Royal Marsden NHS Foundation Trust, United Kingdom. Electronic address: [email protected].

PMID: 28242501
DOI: 10.1016/j.ejca.2016.12.040

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized*
Humans
Ipilimumab*
Melanoma
Nivolumab

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Ipilimumab
Nivolumab
pembrolizumab